After a slow summer, the local venture industry appears to be picking up the pace of its investments as the year comes to a close.
Eight Bay Area startups announced they'd raised new funding rounds in recent days, led by Vial Health Technology. Founded two years ago, the San Francisco company, which helps drug developers organizer and conduct clinical trials, raised a $67 million Series B round.Vial Health Technology Inc., San Francisco, $67 million: General Catalyst led the Series B round for this organizer of clinical trials. Byers Capital and BoxGroup also invested., San Francisco, $60 million: General Catalyst led the Series B round for this provider of an online wedding planning and gift registry service. The company also announced that former Taskrabbit CEO Stacy Brown-Philpot was joining Joy's board of directors.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
San Francisco nonprofit developer HomeRise appoints Interim CEO, CFO - San Francisco Business TimesHomeRise, formerly Community Housing Partnership, oversees a portfolio of roughly 1,600 units in San Francisco and the Bay Area.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »
Rezo Therapeutics, Prosper Marketplace score $75M venture rounds - San Francisco Business TimesThe Thanksgiving holiday didn't stop a drug developer and an online lender from each raising a large new round.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »
Nkarta CEO Paul Hastings: Diversity wins in midterms - San Francisco Business TimesThe CEO of Nkarta, a South S.F. biotech, weighs in on an LGBTQ+ wave and what it means for business.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »
Office markets with biggest gains in sublease space, ranked - San Francisco Business TimesAlthough the analysis doesn't include every U.S. market, it provides a snapshot into how geographically disparate growth in sublease inventory is — and that no city is immune to company decisions to downsize or entirely exit office spaces.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »
Startup Mahzi Therapeutics targets autism, epilepsy related rare genetic brain disorders - San Francisco Business TimesThe 10-employee company, including veterans of rare disease drug developer Ultragenyx Pharmaceutical, has gathered $47.3 million.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »